about
Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysisMicroRNAs in HBV-related hepatocellular carcinoma: functions and potential clinical applicationsIL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitis")?Chronic hepatitis B therapy: available drugs and treatment guidelines.Endocrine manifestations of chronic HCV infection.Usefulness of fecal calprotectin determination in pediatric intestinal diseases.Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α.Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis.Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response.Chronic hepatitis C virus infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and B-cell non-Hodgkin lymphoma.Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers.Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner.Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays.Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.Serum Cytokeratin-18 Levels for Liver Fibrosis PredictionOutcome of chronic delta hepatitis in Italy: a long-term cohort study.Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C.Re: El-Garem et al.: Seminal Helicobacter pylori Treatment Improves Sperm Motility in Infertile Asthenozoospermic Men (Urology 2014;84:1347-1350).DAT1 VNTR polymorphisms in a European and an African population: identification of a new allele.Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test.The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets.Fecal calprotectin: beyond intestinal organic diseases.Management of Helicobacter pylori in Piedmont, Italy.Role and function of exosomal miR-9-3p in hepatocellular carcinoma.Liver fibrosis: the 2017 state of art.Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection.Hepatitis B core-related antigen: a novel biomarker for chronic hepatitis B treatment.L-arginine, apoptosis and gastric cancer: any role for Helicobacter pylori?Biochemical markers of bone metabolism during early orthodontic tooth movement with aligners.Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease.Comment on "Changes in acute viral hepatitis epidemiology in the Turkish adult population: A multicenter study"Serum zonulin in patients with inflammatory bowel disease: a pilot studyHighly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detectionFecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders
P50
Q26775491-BA1125D1-F872-4625-9849-944AF326D55DQ28088776-95253582-7D5D-47F7-930D-CFB89E2913B5Q34255562-EFBC50C4-233F-4094-B2D0-BB25D6C7B94DQ36664505-329CD9A0-E293-4D99-B8E0-ED7D3C5DCBDBQ37413756-C614E059-4C8E-41E7-999B-66E1326755C0Q38260891-26F941BD-656D-4D04-91CB-E5D4EC375667Q38583008-FF676372-406D-491F-B572-AA2180B42D17Q38964466-DFDC4D4A-30F3-45F9-8E4F-D8F9ABAC55D3Q40557516-6587225B-A24C-41DD-AF42-33DDE5C223C4Q40931840-BA3DD5AB-7EF6-46A2-ABBC-5D8C948DF701Q41217279-2340196B-2854-4BAC-813B-2F7D5D663C5CQ41686441-BBDE83AF-ACC2-43C7-8AEA-2BF080D7AA2AQ41747866-BBC2F100-6671-445B-B27E-7CD7F927B177Q42209321-FCE2BB14-DEAF-4791-83BB-BFAB769D11CCQ42212421-AB319D00-D6C5-49BD-BD2B-FB539DC55C53Q42251613-958D8FD8-0B46-4FE5-9FC7-628A3A789FE2Q42286670-D77F8C4C-EC5A-49D3-81E9-73F500E6E8D9Q42754440-C61E693C-AD17-4E75-ACD4-7D93E249FFABQ42923609-6CDC3D60-2190-447E-B36B-D141D16CCCE1Q42987060-94B3CC70-46BD-4400-8427-20F4A9A2067EQ44758192-DDD46E86-1855-46CA-95CD-4E7B03467917Q46415950-B5291804-3CA2-4016-B620-40148D0F4BE1Q47253648-47C46674-6420-4966-B804-D66B2C2E90ECQ47803154-E46CB3F8-0BC3-494B-B496-E8B585C279EDQ47833669-73C8354C-6A8F-491D-B341-D0145C1D28B1Q48140215-55206D8D-3E39-4A67-9CAC-65D2BDE3B7F9Q49688049-AEA4D21C-115B-42A3-9065-3CDEFC458F3BQ49845016-AD6F5F55-D7B4-4DFC-9B01-F5E9624E6567Q50180454-6AA06339-FEFE-4888-A8F0-7EC0A6F0420BQ50208583-7390F352-CAC1-435A-9022-9731A34B1868Q50561205-8B7EB7A3-C842-4C93-ADFF-6A22F3A4CC88Q52604439-F370618F-A756-4D94-BD23-C11E7D7A0053Q53182010-C7FDBF41-9FCC-4910-B6C9-FF12A94801A4Q53190872-220555E7-EC85-4268-BDC0-A7780F3F050EQ53743037-79B6C83A-4E58-4462-BB3D-F0CF585ED183Q53813254-0C86AEBA-AC32-46E7-96ED-FE831CED06C0Q56986458-5E05E83D-E64E-44A5-A7EE-768B017F1228Q57124768-81C11470-7936-4C62-ACA8-82802081308AQ85393270-07166B42-DC33-4570-9062-6BC86CE4F7EBQ85908507-676AD06B-7FF9-4436-A228-07BBE3D84A45
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gian Paolo Caviglia
@ast
Gian Paolo Caviglia
@en
Gian Paolo Caviglia
@es
Gian Paolo Caviglia
@nl
Gian Paolo Caviglia
@sl
type
label
Gian Paolo Caviglia
@ast
Gian Paolo Caviglia
@en
Gian Paolo Caviglia
@es
Gian Paolo Caviglia
@nl
Gian Paolo Caviglia
@sl
prefLabel
Gian Paolo Caviglia
@ast
Gian Paolo Caviglia
@en
Gian Paolo Caviglia
@es
Gian Paolo Caviglia
@nl
Gian Paolo Caviglia
@sl
P106
P1153
24491739500
P21
P31
P496
0000-0002-0529-9481